What analysts say:
- Buy, sell, or hold?: The majority of analysts back Bio-Rad Laboratories as a buy. But with 60% of analysts rating it a buy, Bio-Rad Laboratories is still below the mean analyst rating of its nearest 10 competitors, which average 60.3% buys. Analysts don't like Bio-Rad Laboratories as much as competitor Cepheid overall. Ten out of 14 analysts rate Cepheid a buy compared to three of five for Bio-Rad Laboratories.
- Revenue forecasts: On average, analysts predict $562.1 million in revenue this quarter. That would represent a rise of 5.3% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $1.65 per share. Estimates range from $1.51 to $1.79.
What our community says:
CAPS All-Stars are enthusiastically backing the stock, with 100% giving it an "outperform" rating. The greater community concurs with the All-Stars, as 95.7% give it a rating of "outperform." Even with a robust four out of five stars, Bio-Rad Laboratories' CAPS rating falls a little short of the community's upbeat outlook.
Bio-Rad Laboratories' profit has risen year over year by an average of 20.5% over the past five quarters. Revenue has now gone up for three straight quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Bio-Rad Laboratories now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.